569250-U
Discovery® HS C18 (3 µm) HPLC Columns
L × I.D. 5 cm × 4.6 mm, HPLC Column
别名:
Discovery RP18 HPLC Column
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
L × i.d.:
5 cm × 4.6 mm
Particle size:
3 μm
Matrix active group:
C18 (octadecyl) phase
Pore size:
120 Å
Matrix:
silica gel, high purity, spherical particle platform, fully porous particle
产品名称
Discovery® HS C18 高效液相色谱柱, 3 μm particle size, L × I.D. 5 cm × 4.6 mm
material
stainless steel column
Quality Level
agency
suitable for USP L1
product line
Discovery®
feature
endcapped
manufacturer/tradename
Discovery®
packaging
1 ea of
extent of labeling
20% Carbon loading
parameter
≤70 °C temp. range, 400 bar pressure (5801 psi)
technique(s)
HPLC: suitable, LC/MS: suitable
L × I.D.
5 cm × 4.6 mm
surface area
300 m2/g
surface coverage
3.2 μmol/m2
impurities
<10 ppm metals
matrix
silica gel, high purity, spherical particle platform, fully porous particle
matrix active group
C18 (octadecyl) phase
particle size
3 μm
pore size
120 Å
operating pH range
2-8
application(s)
food and beverages
separation technique
reversed phase
Application
- A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.: This study developed a robust RP-HPLC method to determine molnupiravir in various nanoformulations, showcasing its potential application in permeability studies and ensuring drug stability (Reçber et al., 2022) (Reçber et al., 2022).
- Analysis of terizidone in plasma using HPLC-UV method and its application in a pharmacokinetic study of patients with drug-resistant tuberculosis.: This research presented an HPLC-UV method for analyzing terizidone in plasma, facilitating its use in pharmacokinetic studies of patients with drug-resistant tuberculosis (Mulubwa and Mugabo, 2018) (Mulubwa and Mugabo, 2018).
- Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies.: The study optimized an LC method for quantifying doxorubicin in plasma and urine, crucial for pharmacokinetic, biomedical, and drug monitoring therapy applications (Maliszewska et al., 2018) (Maliszewska et al., 2018).
Features and Benefits
- 稳定性好、低流失，适用于 LC-MS 分析
- 提供有适用于分析型到制备型的各种规格
- 稳定性好，以确保柱与柱和批与批之间之间优良的重现性
- 更强的疏水性能够更好地分离难分析化合物
Legal Information
Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under Discovery® HS C18 高效液相色谱柱
相关内容
HPLC DiscoveryBIO HS C18 products. Available in 3µm, 5µm and 10µm particle sizes.
Swati Jaiswal et al.
Journal of chromatographic science, 55(6), 617-624 (2017-03-24)
Tuberculosis (TB) with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome represents the most common infectious diseases worldwide. Anti-TB drugs are used concurrently with antiretroviral drug for treatment of TB-HIV co-morbidities. Due to lower risk of interaction with protease inhibitors, rifabutin is
Jolanta Flieger et al.
Journal of separation science, 34(7), 733-739 (2011-03-02)
Highly hydrophilic compounds belonging to biogenic amines were analysed in the reversed-phase system, modified with the addition of ionic liquids: 1-ethyl-3-methyl-imidazolium hexafluorophosphate (EMIM PF(6)) and chaotropic salt NaPF(6) on Discovery HS C18 column at acidic conditions. The effect of the
Abad Khan et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 878(28), 2782-2788 (2010-09-11)
A rapid, inexpensive, sensitive and specific HPLC-ECD method for the determination of lipoic acid in human plasma was developed and validated over the linearity range of 0.001-10μg/ml using naproxen sodium as an internal standard (IS). Extraction of lipoic acid and
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 569250-U | 04061838545763 |